Antibodies binding 4-1BB and uses thereof
AssigneeNanjing Leads Biolabs Co., Ltd.
InventorsXiaoqiang Kang, Xiao Huang, Jianming Sun
Life of this patent
Estimating the term…
Abstract
Disclosed is an isolated monoclonal antibody that specifically binds human 4-1BB, or the antigen-binding portion thereof. A nucleic acid molecule encoding the antibody, an expression vector, a host cell and a method for expressing the antibody are also provided. The present disclosure further provides a bispecific molecule, and a pharmaceutical composition comprising the antibody or the bispecific molecule, as well as a treatment method using an anti-4-1BB antibody of the disclosure.
Claims19
An antibody or an antigen-binding portion thereof that binds to 4-1BB, comprising heavy chain variable region CDR1, CDR2 and CDR3 and light chain variable region CDR1, CDR2 and CDR3, wherein
- (i) the heavy chain variable region CDR1, CDR2 and CDR3 comprise the sequences of SEQ ID NOs:
- 1, 2 and 3 respectively, and the light chain variable region CDR1, CDR2 and CDR3regions comprise the sequences of SEQ ID NOs:
- 4, 5 and 6 respectively;
- (ii) the heavy chain variable region CDR1, CDR2 and CDR3 comprise the sequences of SEQ ID NOs:
- 7, 8 and 9 respectively, and the light chain variable region CDR1, CDR2 and CDR3regions comprise the sequences of SEQ ID NOs:
- 10, 11 and 12 respectively;
- (iii) the heavy chain variable region CDR1, CDR2 and CDR3 comprise the sequences of SEQ ID NOs:
- 13, 14 and 15 respectively, and the light chain variable region CDR1, CDR2 and CDR3comprise the sequences of SEQ ID NOs:
- 16, 17 and 18 respectively;
- or
- (iv) the heavy chain variable region CDR1, CDR2 and CDR3 comprise the sequences of SEQ ID NOs:
- 19, 20 and 21 respectively, and the light chain variable region CDR1, CDR2 and CDR3comprise the sequences of SEQ ID NOs:
- 22, 23 and 24 respectively.
Dependencies are inferred from the claim text.